Skip to content

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Report on anterior segment inflammation and immunity posted

Report summarizes discussions form April 2021 meeting
February 2, 2022
Cornea Immunology
NEI
Anterior Segment Initiative

NEI has published an executive summary from the April 23, 2021, virtual workshop “Immunity and Inflammation in the Anterior Segment of the Eye," hosted by the NEI Anterior Segment Initiative.

Green iris

A styled iris. Image credit: National Eye Institute

Eye inflammation is the fifth leading cause of blindness in the U.S. with estimated costs similar to that of diabetic retinopathy. Host mechanisms that regulate immunity play a critical role in ocular inflammation, even in conditions not typically considered “immune-based,” since immunity regulates not just inflammation but also host tissue response to various stressors. These include diabetic retinopathy, age-related maculopathies, and glaucoma, among others. In 2019, the National Eye Institute (NEI) launched the Anterior Segment Initiative to better understand inflammation and its relationship with ocular pain, dry eye disease, the microbiome, and other eye conditions.

The workshop identified relevant gaps in knowledge, barriers to the development of new therapies, and promising areas for research exploration.